Advances in severe hemorrhagic transformation after intravenous thrombolysis with recombinant tissue plasminogen activator for acute brain infarction

WANG Qinying; ZHAN Qing

doi:10.12022/jnnr.2017-0003

PDF(1664 KB)

Journal of Neurology and Neurorehabilitation ›› 2017, Vol. 13 ›› Issue (1) : 25-31. DOI: 10.12022/jnnr.2017-0003

Review

Advances in severe hemorrhagic transformation after intravenous thrombolysis with recombinant tissue plasminogen activator for acute brain infarction

WANG Qinying, ZHAN Qing

Author information +

History +

Abstract

Severe hemorrhagic transformation is a most dangerous complication during thrombolytic therapy for acute ischemic stroke. This paper summarizes the definition, clinical manifestations, imaging characteristics, and the related risk factors of thrombolysis-associated severe hemorrhagic transformation. In acute ischemic stroke patients with high risk of severe hemorrhagic transformation, thrombolytic therapy with a low dose of recombinant tissue plasminogen activator (rtPA) may reduce the risk of symptomatic intracerebral hemorrhage.

Key words

Stroke / Brain infarction / Acute ischemic stroke / Thrombolytic therapy / Symptomatic intracranial hemorrhages / Hemorrhagic transformation

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Qinying, ZHAN Qing. Advances in severe hemorrhagic transformation after intravenous thrombolysis with recombinant tissue plasminogen activator for acute brain infarction[J]. Journal of Neurology and Neurorehabilitation. 2017, 13(1): 25-31 https://doi.org/10.12022/jnnr.2017-0003

References

[1] Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)[J]. JAMA, 1995, 274(13):1017-1025.
[2] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group[J]. N Engl J Med, 1995, 333(24):1581-1587.
[3] Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008, 359(13):1317-1329.
[4] Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASSII). Second European-Australasian Acute Stroke Study Investigators[J]. Lancet, 1998, 352(9136):1245-1251.
[5] Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke[J]. JAMA, 1999, 282(21):2019-2026.
[6] Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study[J]. Lancet, 2007, 369(9558):275-282.
[7] IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial[J]. Lancet, 2012, 379(9834):2352-2363.
[8] IST-3 collaborative group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial[J]. Lancet Neurol, 2013, 12(8):768-776.
[9] Larrue V, von Kummer RR, Müller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASSII)[J]. Stroke, 2001, 32(2):438-441.
[10] Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials[J]. Lancet, 2004, 363(9411):768-774.
[11] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4):246-257.
[12] Kellert L, Sykora M, Gumbinger C, et al. Blood pressure variability after intravenous thrombolysis in acute stroke does not predict intracerebral hemorrhage but poor outcome[J]. Cerebrovasc Dis, 2012, 33(2):135-140.
[13] Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians[J]. Thromb Haemost, 2002, 87(3):544-546.
[14] Ross AM, Gao R, Coyne KS, et al. A randomized trial confirming the efficacy of reduced dose recombinant plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial[J]. Am Heart J, 2001, 142(2):244-247.
[15] Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT)[J]. Stroke, 2006, 37(7):1810-1815.
[16] Chao AC, Hsu HY, Chung CP, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study[J]. Stroke, 2010, 41(5):885-890.
[17] Cronin CA, Shah N, Morovati T, et al. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria[J]. Stroke, 2012, 43(6):1684-1686.
[18] Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study[J]. CMAJ, 2005, 172(10):1307-1312.
[19] Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey[J]. Circulation, 2002, 105(14):1679-1685.
[20] Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator[J]. Stroke, 2004, 35(9):2123-2127.
[21] Inzitari D, Giusti B, Nencini P, et al. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death[J]. Stroke, 2013, 44(10):2901-2903.